Evaxion Biotech A/S — Form 6-K Summary
Business context and reporting period
Evaxion Biotech A/S, a Danish foreign private issuer, filed this Form 6-K on February 2, 2023 for the month of February 2023. The filing reports activity under the company’s at-the-market offering program and provides notice of an extraordinary general meeting scheduled for February 21, 2023.
Key financial and capital markets metrics
- Between December 7, 2022 and January 23, 2023, the company sold 1,143,883 American Depositary Shares (ADSs), with each ADS representing one ordinary share.
- The aggregate volume-weighted average price was $1.83 per ADS.
- Net proceeds after fees and expenses were approximately $2,043,620.
- The issuances increased nominal share capital by DKK 1,143,883, to aggregate nominal share capital of DKK 25,278,846.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or cash-balance data.
Material changes versus the prior comparable period
The filing does not provide a prior-period income statement or operating comparison. The material reported change is the issuance of 1,143,883 ADSs and the resulting increase in share capital, which represents equity financing and dilution for existing shareholders.
Guidance, outlook, risks, contingencies, and unusual items
- The filing provides no financial guidance or operating outlook.
- The equity sales were conducted under the Capital Demand Sales Agreement with Jones Trading Institutional Services LLC dated October 3, 2022.
- The company amended its Articles of Association to reflect the share issuances; the amended articles were filed as Exhibit 1.1.
- An extraordinary general meeting is scheduled for February 21, 2023 at 5:00 p.m. CET. The convening notice was filed as Exhibit 99.1.
- The filing is incorporated by reference into specified Form S-8, Form F-3, and Form F-1 registration statements, to the extent not superseded by later filings.
Investor verification priorities
- Verify the final number of ADSs issued, the $1.83 VWAP, and approximately $2.04 million of net proceeds.
- Assess the effect of the new shares on existing shareholders’ ownership and dilution.
- Review the amended Articles of Association and the extraordinary general meeting agenda.
- Consult subsequent filings for the company’s cash runway, operating expenses, liquidity, and any additional ATM sales.